Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer

by Mauricio eBurotto, Nishith eSingh, Christopher R Heery, James L. Gulley, Ravi Amrit Madan
Published 2014-12-01

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients not Detected in Analysis of Standard Immune Cell...

by Lauren M. Lepone, Renee N. Donahue, Italia Grenga, Simon Metenou, Jacob Richards, Christopher R. Heery, Ravi A. Madan, James L. Gulley, Jeffrey Schlom
Published 2016-03-01

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell...

by Lauren M. Lepone, Renee N. Donahue, Italia Grenga, Simon Metenou, Jacob Richards, Christopher R. Heery, Ravi A. Madan, James L. Gulley, Jeffrey Schlom
Published 2016-03-01

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

by Christopher R Heery, Beatriz Walter-Rodriguez, Seth M Steinberg, Guinevere Chun, Stephanie A Harmon, Ismail Baris Turkbey, Peter L Choyke, William L Dahut, Peter A Pinto
Published 2020-06-01

Correction: Defining current gaps in quality measures for cancer immunotherapy: consensus report from the society for immunotherapy of cancer (SITC) 2019 Quality Summit

by Christopher R Heery, Beatriz Walter-Rodriguez, Seth M Steinberg, Guinevere Chun, Stephanie A Harmon, Ismail Baris Turkbey, Peter L Choyke, William L Dahut, Peter A Pinto
Published 2020-06-01

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

by Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom, James L. Gulley
Published 2019-09-01

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

by Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
Published 2019-10-01